Press Release
Press Release
Nov 25, 2019
Teckro Adds New Products Following Sky-High User Adoption
Meet Teckro: the machine-learning platform revolutionizing the way clinical trials are run.
Press Release
Jul 18, 2019
Teckro Announces 45 High Tech Jobs in Dublin
Main expansion is in Dublin-based Engineering Excellence Hub as Teckro heavily invests in product development to simplify and modernize clinical research  LIMERICK, IRELAND - Teckro, the indigenous Irish firm transforming clinical trials for leading pharmaceutical and emerging biotech companies today officially announced 45 high-end tech jobs for Dublin, representing more than 100% growth in staff here. The company currently has more than 110 employees with offices in Limerick and the US, but the majority of the new roles will be in the company’s Engineering Excellence Hub in Dublin’s Silicon Docks. The technical jobs will span functions across engineering, data science, design and usability, quality and product management. The staff expansion follows the recent appointments of Anita Callan as Vice President of Product, most recently from Aer Lingus, and Neil Flanagan as Vice President of Engineering, previously with Munich Re to Teckro’s leadership team. Speaking at the announcement CEO and Co-Founder Gary Hughes said, “Although technology has revolutionized so many industries, the experience of participating in a clinical trial if you are a doctor, research nurse or patient has not changed in the last two decades. The industry still heavily relies on paper and inefficient processes. At Teckro, we are on a mission to simplify the process and make clinical trials more accessible for everyone involved. We are looking for more talented people, especially in technical roles, to join us and make an impact.”  The company, founded in 2015 by brothers Gary and Nigel Hughes and CTO Jacek Skrzypiec, is currently in scale out mode. This is the second startup founded in Ireland by the Hughes brothers and Skrzypiec, whose previous business, Firecrest Clinical, was sold to Nasdaq-listed clinical research giant ICON in 2011. Teckro provides solutions to simplify and modernize clinical research for leading pharmaceutical and biotech companies, currently managing more than 100 clinical trials and actively used by more than 11,800 study sites worldwide. Earlier this year the company announced a Series C funding round from major US venture capital firms, including Founders Fund, Bill Maris’ Section 32, Borealis Ventures, Northpond Ventures and Sands Capital Ventures that brought its total funding to $43 million and making it one of the fastest growing venture-backed companies developing product in Ireland. Minister for Business, Enterprise and Innovation Heather Humphreys welcomed the jobs saying, “It’s great to see an Irish company based in Dublin and Limerick succeed and grow internationally, especially one with a mission that will ultimately benefit patients and healthcare professionals in research to address global health problems. These 45 new tech jobs will play an important role for Teckro to deliver solutions from Ireland that will improve the clinical trial process throughout the world. This is another great example of how our SMEs are investing in new technologies, which is an important element in our Future Jobs Ireland strategy.” About Teckro Teckro clinical trial software transforms the study protocol into actionable data for everyone – research staff, CROs and sponsors. Global pharmaceuticals and emerging biotechs alike digitize their clinical trials with Teckro. Headquartered in Ireland, Teckro has locations across Europe and the United States. Visit www.teckro.com for more information.
Press Release
Jul 02, 2019
Teckro Expands Leadership Team
Founders Fund-backed company announces 5 senior hires with domain experience from publicly traded companies including Veeva Systems, Salesforce, ICON and Munich Re LIMERICK, IRELAND - Teckro, the company transforming clinical trials for the world’s leading pharmaceutical and emerging biotech firms, today announced five significant appointments to its leadership team as it executes aggressive go-to-market and product strategies. The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms, including Founders Fund, Bill Maris’ Section 32, Borealis Ventures, Northpond Ventures and Sands Capital Ventures. To date, Teckro has raised $43 million, with the latest round of $25 million earmarked for scale-up activities to accelerate growth and meet a sharp increase in demand from pharmaceutical and biotech companies looking to simplify and modernize clinical trials with Teckro. Speaking on the appointments to the leadership team, Teckro CEO and co-founder Gary Hughes said, “Every clinical trial starts with a question. At Teckro, we believe that finding answers should be simple for all study stakeholders anytime, anywhere. The new leadership appointments are important as we continue to expand our product and commercial strategies. I am delighted to have this group of seasoned professionals from established public companies join Teckro on our mission to simplify and modernize clinical research.” Teckro’s new hires bring vast experience across domains, including medical affairs, commercial and engineering: Professor Brendan Buckley, Chief Medical Officer With more than four decades in academic clinical practice, Buckley brings extensive experience as a senior clinical investigator. Buckley has served in several independent regulatory roles in the European Medicines Agency (EMA) and the Irish competent authority. With more than 150 scientific papers published, Buckley also authored the recent opinion-leading book Re-Engineering Clinical Trials. From 2011-2017, Buckley served as Chief Medical Officer and Executive Vice President of ICON, one of the world’s largest clinical research organizations. Kelly Brown, Chief Marketing Officer and Sandra Blaser, VP of Services & Success Also joining Teckro from global life science software giant Veeva Systems are Kelly Brown and Sandra Blaser as Chief Marketing Officer and Vice President of Services & Success, respectively. Brown, previously VP of Marketing in Europe at Veeva, brings more than a decade of experience in the technology sector, including an 11-year stint at EMC (now Dell EMC). Early in her career, Blaser was one of first European employees at Salesforce and served as its first-ever customer success manager in the region. Before joining Teckro, Blaser spent more than five years at Veeva where she managed the customer success team in Europe. Anita Callan, VP of Product and Neil Flanagan, VP of Engineering On the technical side, Teckro bolsters its team with two seasoned professionals, Anita Callan and Neil Flanagan, who collectively will use their vast experience to ensure Teckro’s products meet and exceed customer expectations. Callan joins as Vice President of Product, most recently working at Aer Lingus where she held product and content strategy positions. Flanagan joins as Teckro Vice President of Engineering with extensive experience in building and running highly scalable technology teams. Prior to Teckro, Flanagan most recently was Head of Digital Operations at Munich Re, one of the world’s largest reinsurance companies. Collectively, these new leaders are instrumental in Teckro’s mission to simplify and modernize clinical research. Demand is strong as the number of trials on Teckro has more than tripled over the past couple of years. Today, more than active 11,800 study sites use Teckro in all major countries around the world. Equally important, user adoption of Teckro is high, with more than 90% of registered users active on the platform. About Teckro Teckro clinical trial software transforms the study protocol into actionable data for everyone – research staff, CROs and sponsors. Global pharmaceuticals and emerging biotechs alike digitize their clinical trials with Teckro. Headquartered in Ireland, Teckro has locations across Europe and the United States. Visit www.teckro.com for more information.
Press Release
Feb 14, 2019
Teckro Raises $25 Million Series C Round to Speed up Clinical Trials
Teckro is a technology platform that makes the conduct of clinical trials simple, more transparent and more inclusive for doctors, research nurses and patients  Teckro’s total funding rises to $43 million to date from the likes of Northpond Ventures, Founders Fund and Bill Maris’ Section 32  LIMERICK, IRELAND - Teckro has raised a fresh round of funding to accelerate its international expansion and product development. The $25 million Series C round was led by Northpond Ventures with participation from Founders Fund, Sands Capital Ventures, Bill Maris’ Section 32 venture fund, and Borealis Ventures. Teckro’s total funding now stands at $43 million. The company provides technology to improve the speed and accuracy of clinical trials, working with the top pharmaceutical and biotech companies globally. Teckro has grown rapidly since it was founded by brothers Gary and Nigel Hughes and Jacek Skrzypiec in 2015. The founders sold their previous company, Firecrest, to global clinical research giant ICON plc in 2011. Teckro is used in clinical research sites around the world in all major countries. There has been a 240% increase in the number of clinical trials on the Teckro platform over the past 12 months. The company employs more than 100 staff across its three global bases, including its global headquarters in Limerick, Ireland, its engineering hub in Dublin, Ireland and its US office in Nashville, Tennessee.  Speaking on the funding announcement, CEO and co-founder Gary Hughes said the company will use the Series C round to further the company’s mission to deliver solutions that deliver meaningfully impact and improve processes for all stakeholders involved in clinical trials. “Despite all the talk of digital transformation, the actual experience of participating in a clinical trial if you are a doctor, research nurse or patient has changed little in the last 20 years. The industry still relies heavily on paper, on working off retrospective data, and there is still an over-reliance on sending CRAs to busy research sites. This approach, together with the plethora of point solutions that get ‘bolted on’, only adds to the complexity and disjointed experience of research sites and patients. Our vision is to be at the center of all site and patient interactions in a clinical trial. We are building a new digital infrastructure and toolset for clinical research that makes the conduct of trials simpler, more transparent and more inclusive. Ultimately Teckro is about ensuring that effective drugs are efficiently and effectively moved from the lab to the patient so that lives be saved.” Michael Rubin, M.D., Ph.D., Founder & CEO of Northpond Ventures commented: “Teckro is building a digital infrastructure that can transform how clinical trials are conducted. We are excited by the team and what they have achieved to date and look forward to supporting them on this important mission.” About Teckro Teckro clinical trial software transforms the study protocol into actionable data for everyone – research staff, CROs and sponsors. Global pharmaceuticals and emerging biotechs alike digitize their clinical trials with Teckro. Headquartered in Ireland, Teckro has locations across Europe and the United States. Visit www.teckro.com for more information.